The National Health Commission of the People's Republic of China issued guidance clarifying regulations related to clinical research and translational applications of new biomedical technologies. The update supports innovation while strengthening compliance expectations.
Key highlights:
- Clarifies Regulatory expectations for clinical research
- Supports translational application of innovative therapies
- Impacts advanced therapies and novel drug developers
- Strengthens compliance oversight for emerging technologies
This update is relevant for companies involved in innovative drug development in China."
Source
Select Mandate HA
Select Mandate Function